HK Stock Market Move | CSTONE PHARMA-B(02616) rose over 7% in early trading. The company presented the phase I clinical trial data of CS2009 for the first time at the 2025 ESMO Annual Meeting.

CSTONE PHARMA-B(02616) rose more than 5% in early trading, up 7.41% to 7.39 Hong Kong dollars as of press time, with a turnover of 54.6548 million Hong Kong dollars. On the news front, CStone Pharma announced that it has presented preliminary data from the Phase I clinical study of CS2009 (PD1/VEGF/CTLA-4 trispecific antibody) and the Phase Ib clinical study design of CS5001 (ROR1 antibody-drug conjugate ADC) for the first time at the 2025 ESMO Annual Meeting. It is worth noting that according to the latest information from the Hong Kong Stock Exchange, GIC disclosed on October 13 that it has once again increased its stake in CStone Pharma to 6%. This is the second major increase by GIC in less than two monthspreviously, on August 18, GIC significantly increased its stake in CStone Pharma by 80.4 million shares, spending over 630 million Hong Kong dollars.